Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages e1680-

  Marshall, B ^a   Puthalakath, H ^a   Caria, S ^a   Chugh, S ^a,d   Doerflinger, M ^a   Colman, P M ^b,c   Kvansakul, M ^a,b  

^a LA TROBE UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BH3 PROTEIN; BIM PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; UNCLASSIFIED DRUG; VACCINIA VIRUS F1L; VARIOLA VIRUS F1L; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; ONCOPROTEIN; VIRAL PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; EMBRYO; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; SMALLPOX VIRUS; TROPISM; VACCINIA VIRUS; VIRUS NEUTRALIZATION; CELL LINE; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE; HUMANS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; VARIOLA VIRUS; VIRAL PROTEINS;

EID: 84931008001     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.52     Document Type: Article

References (56)

1. Kaiser J. Smallpox vaccine. A tame virus runs amok. Science 2007; 316: 1418-1419.
2. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005; 23: 2078-2081.
3. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA et al. Vaccinia virus vaccines: past, present and future. Antiviral Res 2009; 84: 1-13.
4. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 2003; 58: 101-114.
5. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holy A et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 2006; 439: 745-748.
6. Baker R, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003; 57: 13-23.
7. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005; 79: 13139-13149.
8. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005; 11: 731-739.
9. Yang HL, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005; 115: 379-387.
10. Fauci AS, Challberg MD. Host-based antipoxvirus therapeutic strategies: turning the tables. J Clin Invest 2005; 115: 231-233.
11. Sliva K, Schnierle B. From actually toxic to highly specific - novel drugs against poxviruses. Virol J 2007; 4: 8.
12. Graham KA, Opgenorth A, Upton C, McFadden G. Myxoma virus M11L ORF encodes a protein for which cell surface localization is critical in manifestation of viral virulence. Virology 1992; 191: 112-124.
13. Banadyga L, Lam SC, Okamoto T, Kvansakul M, Huang DC, Barry M. Deerpox virus encodes an inhibitor of apoptosis that regulates Bak and Bax. J Virol 2011; 85: 1922-1934.
14. Banadyga L, Veugelers K, Campbell S, Barry M. The fowlpox virus BCL-2 homologue, FPV039, interacts with activated Bax and a discrete subset of BH3-only proteins to inhibit apoptosis. J Virol 2009; 83: 7085-7098.
15. Wasilenko ST, Stewart TL, Meyers AF, Barry M. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc Natl Acad Sci USA 2003; 100: 14345-14350.
16. Okamoto T, Campbell S, Mehta N, Thibault J, Colman PM, Barry M et al. Sheeppox virus SPPV14 encodes a Bcl-2-like cell death inhibitor that counters a distinct set of mammalian proapoptotic proteins. J Virol 2012; 86: 11501-11511.
17. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
18. Kvansakul M, Hinds MG. Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis 2013; 4: e909.
19. Bartlett N, Symons JA, Tscharke DC, Smith GL. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 2002; 83: 1965-1976.
20. Kvansakul M, van Delft MF, Lee EF, Gulbis JM, Fairlie WD, Huang DC et al. A structural viral mimic of prosurvival bcl-2: a pivotal role for sequestering proapoptotic bax and bak. Mol Cell 2007; 25: 933-942.
21. Douglas AE, Corbett KD, Berger JM, McFadden G, Handel TM. Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci 2007; 16: 695-703.
22. Campbell S, Thibault J, Mehta N, Colman PM, Barry M, Kvansakul M. Structural insight into BH3 domain binding of vaccinia virus antiapoptotic F1L. J Virol 2014; 88: 8667-8677.
23. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, Perugini MA et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 2008; 15: 1564-1571.
24. Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, Reed JC et al. Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci 2007; 16: 118-124.
25. Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 2007; 88: 1656-1666.
26. Campbell S, Hazes B, Kvansakul M, Colman P, Barry M. Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1. J Biol Chem 2010; 285: 4695-4708.
27. Fischer SF, Ludwig H, Holzapfel J, Kvansakul M, Chen L, Huang DCS et al. Modified vaccinia virus ankara protein F1L is a novel BH3-domain binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death Differ 2006; 13: 109-118.
28. Taylor JM, Quilty D, Banadyga L, Barry M. The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax. J Biol Chem 2006; 281: 39728-39739.
29. Altmann M, Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 2005; 3: e404.
30. Dobbelstein M, Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol 1996; 70: 6479-6485.
31. Kvansakul M, Hinds MG. The structural biology of BH3-only proteins. Meth Enzym 2014; 544: 49-74.
32. Rautureau GJ, Yabal M, Yang H, Huang DC, Kvansakul M, Hinds MG. The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death Dis 2012; 3: e443.
33. Desbien AL, Kappler JW, Marrack P. The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim. Proc Natl Acad Sci USA 2009; 106: 5663-5668.
34. Kvansakul M, Wei AH, Fletcher JI, Willis SN, Chen L, Roberts AW et al. Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathog 2010; 6: e1001236.
35. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD et al. Bax crystal structures reveal how BH3 domains activate bax and nucleate its oligomerization to induce apoptosis. Cell 2013; 152: 519-531.
36. Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem 2011; 286: 491-501.
37. Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD. BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell 2010; 40: 481-492.
38. Chi X, Kale J, Leber B, Andrews DW. Regulating cell death at, on, and in membranes. Biochim Biophys Acta 2014; 1843: 2100-2113.
39. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Pro-apoptotic Bak is sequestered by Mc1-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Devel 2005; 19: 1294-1305.
40. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
41. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
42. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
43. Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis 2015; 20: 136-150.
44. Aleshin AE, Drag M, Gombosuren N, Wei G, Mikolajczyk J, Satterthwait AC et al. Activity, specificity, and probe design for the smallpox virus protease K7L. J Biol Chem 2012; 287: 39470-39479.
45. Gileva IP, Nepomnyashchikh TS, Ryazankin IA, Shchelkunov SN. Recombinant TNF-binding protein from variola virus as a novel potential TNF antagonist. Biochem Biokhimiia 2009; 74: 1356-1362.
46. Mohamed MR, Rahman MM, Lanchbury JS, Shattuck D, Neff C, Dufford M et al. Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc Natl Acad Sci USA 2009; 106: 9045-9050.
47. Perry K, Hwang Y, Bushman FD, Van Duyne GD. Structural basis for specificity in the poxvirus topoisomerase. Mol Cell 2006; 23: 343-354.
48. Phan J, Tropea JE, Waugh DS. Structure-assisted discovery of Variola major H1 phosphatase inhibitors. Acta Cryst D 2007; 63: 698-704.
49. Kabsch W. Xds. Acta Cryst D 2010; 66: 125-132.
50. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR et al. Overview of the CCP4 suite and current developments. Acta Cryst D 2011; 67: 235-242.
51. Storoni LC, McCoy AJ, Read RJ. Likelihood-enhanced fast rotation functions. Acta Cryst D 2004; 60: 432-438.
52. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Cryst D 2010; 66: 213-221.
53. De Lano WL The PyMOL molecular graphics system, 2002. www.pymol.org.
54. Morin A, Eisenbraun B, Key J, Sanschagrin PC, Timony MA, Ottaviano M et al. Collaboration gets the most out of software. eLife 2013; 2: e01456.
55. Jabbour AM, Puryer MA, Yu JY, Lithgow T, Riffkin CD, Ashley DM et al. Human Bcl-2 cannot directly inhibit the Caenorhabditis elegans Apaf-1 homologue CED-4, but can interact with EGL-1. J Cell Sci 2006; 119: 2572-2582.
56. Vince JE, Wong W, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007; 131: 682-693.